

MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

GALCANEZUMAB FOR PREVENTING MIGRAINE, NICE TA659, NOVEMBER 2020

RED – RECOMMENDED FOR RESTRICTED USE in Secondary Care

| Name: generic (trade) | What it is | Licensed indications | Decision status | NICE guidance |
|---|---|--|-----------------|--------------------------|
| GALCANEZUMAB s/c injection (Emgality®▼) | Analgesic; CGRP antagonist; recombinant humanised monoclonal antibody | Prophylaxis of migraine in adults who have at least four migraine days per month | Final | NICE TA659 – recommended |

MSEMOC recommendation:

Galcanzumab is recommended as an option for preventing migraine in adults in accordance with NICE technology appraisal recommendations.

[NICE TA659](#) recommendation:

1.1 Galcanzumab is recommended as an option for preventing migraine in adults, only if:

- they have 4 or more migraine days a month
- at least 3 preventive drug treatments have failed** and
- the company provides it according to the commercial arrangement.

1.2 Stop galcanzumab after 12 weeks of treatment if:

- in episodic migraine (less than 15 headache days a month) the frequency does not reduce by at least 50%
- in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine) the frequency does not reduce by at least 30%.

1.3 This recommendation is not intended to affect treatment with galcanzumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop

**At least three preventative drug treatments should be in line with those included in the [MSEMOC adult headache pathway](#).

For further information refer to the [Summary of Product Characteristics for galcanzumab](#).

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

| | |
|-------------------------|---|
| References | NICE TA659: Galcanzumab for preventing migraine: https://www.nice.org.uk/guidance/ta659 |
| Acknowledgements | Mid and South Essex CCGs Medicines Management Teams |
| Version | 1.0 |
| Author | HCPMSEMOC working group |
| Approved by | MSEMOC; MSE Joint Committee |
| Date Approved | February 2021; February 2021 |
| Review Date | February 2026 or sooner if subject to any new updates nationally |